Last reviewed · How we verify
Liposomal Mitoxantrone Hydrochloride dose level 1
Liposomal Mitoxantrone Hydrochloride dose level 1 is a Small molecule drug developed by Institute of Hematology & Blood Diseases Hospital, China. It is currently in Phase 1 development.
At a glance
| Generic name | Liposomal Mitoxantrone Hydrochloride dose level 1 |
|---|---|
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (NA)
- Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL (PHASE2)
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PHASE1, PHASE2)
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial (PHASE2)
- Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML (PHASE2)
- Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study (PHASE2)
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies (PHASE2)
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal Mitoxantrone Hydrochloride dose level 1 CI brief — competitive landscape report
- Liposomal Mitoxantrone Hydrochloride dose level 1 updates RSS · CI watch RSS
- Institute of Hematology & Blood Diseases Hospital, China portfolio CI
Frequently asked questions about Liposomal Mitoxantrone Hydrochloride dose level 1
What is Liposomal Mitoxantrone Hydrochloride dose level 1?
Liposomal Mitoxantrone Hydrochloride dose level 1 is a Small molecule drug developed by Institute of Hematology & Blood Diseases Hospital, China.
Who makes Liposomal Mitoxantrone Hydrochloride dose level 1?
Liposomal Mitoxantrone Hydrochloride dose level 1 is developed by Institute of Hematology & Blood Diseases Hospital, China (see full Institute of Hematology & Blood Diseases Hospital, China pipeline at /company/institute-of-hematology-blood-diseases-hospital-china).
What development phase is Liposomal Mitoxantrone Hydrochloride dose level 1 in?
Liposomal Mitoxantrone Hydrochloride dose level 1 is in Phase 1.